Evidence Level:Sensitive: C1 - Off-label
(Approved for Melanoma)
New
Excerpt:Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Excerpt:...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Excerpt:...Tumor samples were then sent to a central laboratory to identify activating BRAF V600 mutations. ...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Excerpt:...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Excerpt:...BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Excerpt:...- Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does...
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Vitamin C sensitizes BRAF V600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
Excerpt:PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer...PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAFMT thyroid cancer.
DOI:10.1186/s13046-021-01831-y